Metabolic and purinergic immune regulation

代谢和嘌呤能免疫调节

基本信息

  • 批准号:
    10826864
  • 负责人:
  • 金额:
    $ 39.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-01 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract: Sepsis is a leading cause of death that kills more than 5 million people annually word-wide. Sepsis involves immune dysfunction that is characterized by excessive inflammation that causes multiple organ dysfunction syndrome (MODS). At the same time, immunosuppression and T cell dysfunction impair host immune defenses, resulting in the unimpeded spread of bacterial infections. Despite intense research efforts in the field, all previous attempts to improve outcome in sepsis have failed and no effective treatments are available. These disappointing results clearly demonstrate the need for a better understanding of the underlying mechanisms that cause immune dysfunction in sepsis. The focus of this laboratory has been to determine the molecular and cellular mechanisms that cause immune dysfunction in trauma, critical care, and sepsis patients. Our long-term goal is to identify novel pharmacological strategies that can prevent excessive inflammation and the immunosuppression responsible for morbidity and mortality in sepsis. We discovered novel signaling mechanisms that regulate neutrophils and T cells and that represent promising therapeutic targets to restore immune homeostasis in sepsis patients. These novel signaling mechanisms regulate cell functions by cellular ATP release and by autocrine feedback through excitatory and inhibitory purinergic receptors that act in synergy with Ca2+ signaling and mitochondrial metabolism to fine-tune the immune cell responses needed for host defense. We found that the subcellular localization and differential activation of mitochondria and purinergic receptors are essential for proper neutrophil and T cell functions. Interfering with these signaling processes impairs the ability of these cells to detect and eliminate invading pathogens. We found that these novel cell signaling pathways are impaired in sepsis patients because excessive systemic ATP that accumulates in the circulation of these patients interferes with the autocrine purinergic signaling mechanisms that regulate immune cell functions. In addition, we found that sepsis impairs the mitochondria that provide the ATP for these purinergic signaling mechanisms. In the proposed MIRA project, we plan to continue our studies in order to define the molecular and cellular mechanisms that lead to immune dysfunction in sepsis. NAD is a nucleotide that functions as a coenzyme for many metabolic processes. We will examine whether and how declining NAD levels in sepsis contribute to mitochondrial dysfunction, immune defects, and poor outcome in sepsis. We will study whether increased expression of CD38 in sepsis is responsible for increased NAD consumption and whether NAD consumption deprives sirtuins of the coenzyme they need to prevent mitochondrial damage and prevent immune cell dysfunction. In addition, we will study how purinergic signaling contributes to the activation and trafficking of mitochondria within T cells and neutrophils and how these regulatory mechanisms are impaired in sepsis. Finally, we will explore how CD38, NAD, and sirtuins can be targeted with pharmacological interventions in order to restore mitochondrial function, purinergic signaling, and immune homeostasis in sepsis patients. The proposed work is innovative and possibly paradigm shifting because it focuses on the novel concept that mitochondria are central regulators of immune cells and that mitochondrial dysfunction is the underlying problem that impairs immune function in sepsis. We propose to exploit this knowledge with innovative treatments that replenish mitochondrial health and purinergic signaling and thereby restore immune function from within the cell. This approach is superior to previous strategies aimed at intercepting stimulatory immune cell signals that failed because these strategies further disrupted immune homeostasis and the ability of the host to fight infections.
项目总结/文摘:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WOLFGANG G JUNGER其他文献

WOLFGANG G JUNGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WOLFGANG G JUNGER', 18)}}的其他基金

Role of purinergic signaling in pediatric multi-organ failure
嘌呤能信号在儿童多器官衰竭中的作用
  • 批准号:
    10671089
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Role of purinergic signaling in pediatric multi-organ failure
嘌呤能信号在儿童多器官衰竭中的作用
  • 批准号:
    10829152
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Administrative Supplement for Equipment Purchase
设备采购行政补充
  • 批准号:
    10797062
  • 财政年份:
    2020
  • 资助金额:
    $ 39.5万
  • 项目类别:
Metabolic and purinergic immune regulation
代谢和嘌呤能免疫调节
  • 批准号:
    10350637
  • 财政年份:
    2020
  • 资助金额:
    $ 39.5万
  • 项目类别:
Role of purinergic signaling in pediatric multi-organ failure
嘌呤能信号在儿童多器官衰竭中的作用
  • 批准号:
    9897607
  • 财政年份:
    2019
  • 资助金额:
    $ 39.5万
  • 项目类别:
Role of purinergic signaling in pediatric multi-organ failure
嘌呤能信号在儿童多器官衰竭中的作用
  • 批准号:
    10361188
  • 财政年份:
    2019
  • 资助金额:
    $ 39.5万
  • 项目类别:
Harvard Trauma Inflammation Training Program
哈佛创伤炎症培训计划
  • 批准号:
    8413941
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
Harvard Trauma Inflammation Training Program
哈佛创伤炎症培训计划
  • 批准号:
    8689119
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
Harvard Trauma Inflammation Training Program
哈佛创伤炎症培训计划
  • 批准号:
    8878299
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
Harvard Trauma Inflammation Training Program
哈佛创伤炎症培训计划
  • 批准号:
    9287778
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:

相似海外基金

Development of biological response modifiers of neurotrophins and their receptors
神经营养素及其受体生物反应调节剂的开发
  • 批准号:
    171953
  • 财政年份:
    2008
  • 资助金额:
    $ 39.5万
  • 项目类别:
    Operating Grants
Collection, Storage, Advertisements, & Distribut of Biological Response Modifiers
收藏、保管、广告、
  • 批准号:
    7789037
  • 财政年份:
    2006
  • 资助金额:
    $ 39.5万
  • 项目类别:
Collection, Storage, Advertisements, & Distribut of Biological Response Modifiers
收藏、保管、广告、
  • 批准号:
    8089733
  • 财政年份:
    2006
  • 资助金额:
    $ 39.5万
  • 项目类别:
Design and development of biological response modifiers
生物反应调节剂的设计和开发
  • 批准号:
    14103018
  • 财政年份:
    2002
  • 资助金额:
    $ 39.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
Enhancement of PDT Using Biological Response Modifiers
使用生物反应调节剂增强 PDT
  • 批准号:
    7624158
  • 财政年份:
    2001
  • 资助金额:
    $ 39.5万
  • 项目类别:
Enhancement of PDT Using Biological Response Modifiers
使用生物反应调节剂增强 PDT
  • 批准号:
    7867872
  • 财政年份:
    2001
  • 资助金额:
    $ 39.5万
  • 项目类别:
ENHANCEMENT OF PDT USING BIOLOGICAL RESPONSE MODIFIERS
使用生物反应调节剂增强 PDT
  • 批准号:
    6616667
  • 财政年份:
    2001
  • 资助金额:
    $ 39.5万
  • 项目类别:
Enhancement of PDT Using Biological Response Modifiers
使用生物反应调节剂增强 PDT
  • 批准号:
    7440233
  • 财政年份:
    2001
  • 资助金额:
    $ 39.5万
  • 项目类别:
ENHANCEMENT OF PDT USING BIOLOGICAL RESPONSE MODIFIERS
使用生物反应调节剂增强 PDT
  • 批准号:
    6758547
  • 财政年份:
    2001
  • 资助金额:
    $ 39.5万
  • 项目类别:
ENHANCEMENT OF PDT USING BIOLOGICAL RESPONSE MODIFIERS
使用生物反应调节剂增强 PDT
  • 批准号:
    6261215
  • 财政年份:
    2001
  • 资助金额:
    $ 39.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了